Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: type 1 diabetes

Barbara Volcker Center Marks 20 Years of Research & Clinical Work

Catherine Kolonko  |  January 19, 2018

Although two decades have ticked by, rheumatologist Michael Lockshin, MD, MACR, still remembers the enlightening nature of many conversations he had with his curious and persistent patient Barbara Volcker, the wife of former U.S. Federal Reserve Chairman Paul Volcker. “The conversations we had at that time led to the mission of the Barbara Volcker Center,”…

Filed under:Professional TopicsProfilesResearch Rheum Tagged with:Barbara Volcker CenterResearch

Neurontin Prescriptions Surge Amid Opioid Crisis

Cindy Devone-Pacheco  |  January 4, 2018

(Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…

Filed under:Drug Updates Tagged with:gabapentinoidsLyricanational opioid addiction epidemicNeurontinNeurontin prescription surgeopioid crisis

A History of the Science, Treatment of Rheumatologic Illnesses from Gold to Gene Therapy

Simon M. Helfgott, MD  |  December 17, 2017

Mysterious Ways The juxtaposition of the old and the new was readily evident that busy Wednesday morning. My first patient, a 94-year-old gentleman, Hal, arrived with a precise request. His rheumatologist for the past 40 years had just retired, and he was searching for a doctor with expertise in the use of gold sodium aurothioglucose,…

Filed under:ConditionsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:American College of Rheumatology (ACR)American Rheumatism AssociationArthritisautoimmune mediated diseasebioinformaticsC-reactive proteinClinicalcorticosteroid drugsDiagnosisgenomicsHistoryimmune-suppressive therapiesinflammationknowledgemedicalpatient careResearchRheumatic Diseaserheumatologysciencetranslational researchTreatment

Rheumatologists Find Nailfold Capillaroscopy an Increasingly Useful Diagnostic Tool

Ruth Jessen Hickman, MD  |  October 18, 2017

Interest in viewing the nail capillaries dates to the late 17th century. Later research by Maurice Raynaud and others in the late 19th and early 20th century first established a direct link between the nailfold capillaries and certain medical conditions. Although underutilized in the past, with the advent of modern digital equipment and the validation…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Clinicaldiagnostic toolnailfold capillaroscopyoffice visitpatient carePractice ManagementRaynaud’s phenomenonrheumatologistrheumatologysymptomSystemic sclerosis

Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

Gene Emery  |  September 22, 2017

(Reuters Health)—In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market. A September 20 online analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done….

Filed under:Drug UpdatesEthics Tagged with:Dartmouth Institute for Health Policy and Clinical PracticeFDA approvalGilenya (fingolimod)Indivior's SuboxoneU.S. Food and Drug Administration

Fellows’ Forum Case Report: Tophaceous Bullae

Mark Vercel, DO, Kim Reinhart, OMS-3, & Amita Thakkar, MD  |  August 13, 2017

As a manifestation of hyperuricemia, inflammatory bullous lesions have rarely been described in the past century. A more classic presentation of hyperuricemia is acute inflammatory gouty arthritis, characterized by the deposition of monosodium urate crystals. Other complications of chronic untreated hyperuricemia may include polyarticular arthritis, tophus formation and possible chronic destructive lesions of the bone,…

Filed under:Conditions Tagged with:case reportClinicalFellowsFellows ForumoutcomeRheumatic DiseaserheumatologyTophaceous Bullae

Is an Arthritis Vaccine Using Genetically Reprogrammed Stem Cells on the Horizon?

Elizabeth Hofheinz, MPH, MEd  |  August 13, 2017

The words genetically modified are making people run for the hills these days. Not so when it comes to arthritis care, however. In the lab of one pioneering researcher, genetic engineering is catapulting arthritis treatment years ahead. Farshid Guilak, PhD, is a professor in the Department of Orthopaedic Surgery at Washington University, St. Louis, and…

Filed under:ConditionsResearch Rheum Tagged with:anti-inflammatory drugArthritisgeneticinflammationResearchRheumatic Diseaserheumatologystem cellvaccine

Progress Made During HOD Annual Meeting

Gary L. Bryant, MD, FACR, FACP  |  July 24, 2017

The AMA House of Delegates (HOD) met in Chicago for its annual meeting June 9–14. More than 530 HOD members were present, with several hundred AMA and association staff and guests. As I am sure you have noted from past issues of ACR@Work, the ACR is in its five-year membership review. The ACR must be…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AMA annual meetingAMA House of Delegates (HOD)AMA membership

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

Michele B. Kaufman, PharmD, BCGP  |  July 20, 2017

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:amputationApprovalsbonecanagliflozindrugFDAFracturesGiant Cell ArteritisMedicationMyocardial infarctionNSAIDOsteoporosisrheumatologyriskromosozumabSafetytocilizumabTreatment

How Global Geographic Disparities Affect Healthcare Outcomes

Simon M. Helfgott, MD  |  July 13, 2017

Your home & your health: Does geography impact medicine? Does it matter whether a region is surrounded by large bodies of water, encircled by towering mountain peaks or that its residents share a common ancestry? Consider Switzerland, a nation with a highly developed economy replete with advanced technological and medical infrastructure. Despite these advantages, less…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:cost of health careDiseaseDisparitiesgeographyglobalHealth InsuranceHealthcareInternationallife expectancymedicinepublic healthrheumatologyTechnology

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences